Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects outcome. Hydroxychloroquine should administered to every patient irrespective organ involvement. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine tacrolimus. However, despite conventional treatment, flares occur broad immunosuppression accompanied multiple side effects. Flare occurrence, target involvement, effects increased knowledge pathogenetic mechanisms involved in SLE pathogenesis as well availability biologic agents has led application management. Biologic targeting various paths have been applied. B cell used successfully. Belimumab, agent, approved for treatment SLE. Rituximab, an anti-CD20 agent also Anifrolumab, interferon I receptor-targeting beneficial on In conclusion, applied further evaluated aim good response significant improvement quality life.